ZVRA · Insider Trading
Zevra Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ZVRA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-13 | Neil F. McFarlane | President and CEO | MIXED | +30,000 | −$224.95K |
| 2026-08-17 | Rahsaan Thompson | Chief Legal & Compliance | Sell | −42,666 | −$474.77K |
| 2026-08-12 | Corey Michael Watton | Director | MIXED | — | −$77.25K |
| 2026-06-23 | Rahsaan Thompson | Chief Legal & Compliance | MIXED | +32,110 | −$438.30K |
| 2026-06-18 | Tamara A Favorito | Director | A | +30,000 deriv. | — |
| 2026-06-18 | Alicia Secor | Director | A | +30,000 deriv. | — |
| 2026-06-18 | Corey Michael Watton | Director | A | +30,000 deriv. | — |
| 2026-06-18 | Thomas Anderson | Director | A | +30,000 deriv. | — |
| 2026-06-18 | Douglas W Calder | Director | A | +30,000 deriv. | — |
| 2026-06-18 | Alvin Shih | Director | A | +30,000 deriv. | — |
| 2026-05-29 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | A | +60,000 deriv. | — |
| 2026-05-13 | Rahsaan Thompson | Chief Legal & Compliance | Sell | −1,794 | −$20.27K |
| 2026-03-26 | John B Bode | Director | M | +78,400 | +$386.51K |
| 2026-03-19 | Justin A Renz | CFO | A | +300,000 deriv. | — |
| 2026-02-10 | Neil F. McFarlane | President and CEO | MIXED | +22,875 | −$125.19K |
| 2026-02-04 | Joshua Schafer | CCO | Sell | −10,500 | −$96.50K |
| 2026-02-04 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Sell | −3,000 | −$27.55K |
| 2026-02-02 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | MIXED | +16,249 | −$15.44K |
| 2026-02-02 | Neil F. McFarlane | President and CEO | MIXED | +142,334 | −$853.43K |
| 2026-02-02 | Adrian W Quartel | Chief Medical Officer | MIXED | +6,800 | −$40.04K |
| 2026-02-02 | Rahsaan Thompson | Chief Legal & Compliance | MIXED | +7,253 | −$36.01K |
| 2026-02-02 | Joshua Schafer | CCO | MIXED | +43,292 | −$29.80K |
| 2026-01-07 | R. LaDuane Clifton | — | MIXED | +92,154 | −$434.68K |
| 2025-12-09 | Alicia Secor | Director | A | +45,000 deriv. | — |
| 2025-10-10 | Neil F. McFarlane | President and CEO | MIXED | +30,500 | −$210.91K |
| 2025-09-16 | Tamara A Favorito | Director | Buy | +3,175 | +$24.72K |
| 2025-09-15 | Alvin Shih | Director | Buy | +20,000 | +$157.80K |
| 2025-08-20 | John B Bode | Director | Buy | +5,000 | +$45.82K |
| 2025-06-30 | Rahsaan Thompson | Chief Legal & Compliance | Sell | −24,000 | −$221.00K |
| 2025-06-24 | Rahsaan Thompson | Chief Legal & Compliance | M | +66,666 | — |
| 2025-05-30 | Alvin Shih | Director | A | +30,000 deriv. | — |
| 2025-05-30 | Tamara A Favorito | Director | A | +30,000 deriv. | — |
| 2025-05-30 | Wendy L Dixon | Director | A | +30,000 deriv. | — |
| 2025-05-30 | Douglas W Calder | Director | A | +30,000 deriv. | — |
| 2025-05-30 | Corey Michael Watton | Director | A | +30,000 deriv. | — |
| 2025-05-30 | John B Bode | Director | A | +30,000 deriv. | — |
| 2025-05-30 | Thomas Anderson | Director | A | +30,000 deriv. | — |
| 2025-03-31 | Corey Michael Watton | Director | Buy | +300 | +$2.35K |
| 2025-03-27 | Adrian W Quartel | Chief Medical Officer | A | +102,000 deriv. | — |
| 2025-03-21 | John B Bode | Director | Buy | +10,000 | +$79.62K |
| 2025-02-14 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | Sell | −3,000 | −$23.59K |
| 2025-02-14 | R. LaDuane Clifton | CFO & Treasurer | Sell | −11,000 | −$86.47K |
| 2025-02-14 | Joshua Schafer | CCO & EVP, Bus. Development | Sell | −10,500 | −$82.53K |
| 2025-02-14 | Neil F. McFarlane | President and CEO | Sell | −91,817 | −$727.39K |
| 2025-02-10 | Neil F. McFarlane | President and CEO | A | +337,500 deriv. | — |
| 2025-02-03 | Timothy J. Sangiovanni | SVP, Finance & Corp Controller | M | +11,666 | — |
| 2025-02-03 | Neil F. McFarlane | President and CEO | M | +233,333 | — |
| 2025-02-03 | R. LaDuane Clifton | CFO & Treasurer | M | +43,333 | — |
| 2025-02-03 | Rahsaan Thompson | Chief Legal & Compliance | A | +102,000 deriv. | — |
| 2025-02-03 | Joshua Schafer | CCO & EVP, Bus. Development | M | +35,333 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Neil F. McFarlane | President and CEO | 437,225 | $4.56M |
| R. LaDuane Clifton | CFO & Treasurer | 143,515 | $1.50M |
| John B Bode | Director | 123,400 | $1.29M |
| Joshua Schafer | CCO | 62,278 | $648.94K |
| Rahsaan Thompson | Chief Legal & Compliance | 37,569 | $391.47K |
| Timothy J. Sangiovanni | SVP, Finance & Corp Controller | 29,590 | $308.33K |
| Alvin Shih | Director | 20,000 | $208.40K |
| Thomas Anderson | Director | 20,000 | $208.40K |
| Adrian W Quartel | Chief Medical Officer | 14,256 | $148.55K |
| Corey Michael Watton | Director | 14,100 | $146.92K |
| Tamara A Favorito | Director | 3,894 | $40.58K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ZVRA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.